Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 4 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 8 | 9 |
| 2003 | 1 | 5 | 6 |
| 2004 | 2 | 9 | 11 |
| 2005 | 2 | 5 | 7 |
| 2006 | 3 | 2 | 5 |
| 2007 | 5 | 6 | 11 |
| 2008 | 7 | 8 | 15 |
| 2009 | 5 | 4 | 9 |
| 2010 | 8 | 18 | 26 |
| 2011 | 3 | 10 | 13 |
| 2012 | 9 | 16 | 25 |
| 2013 | 10 | 13 | 23 |
| 2014 | 11 | 18 | 29 |
| 2015 | 7 | 17 | 24 |
| 2016 | 17 | 12 | 29 |
| 2017 | 13 | 19 | 32 |
| 2018 | 22 | 12 | 34 |
| 2019 | 14 | 21 | 35 |
| 2020 | 14 | 16 | 30 |
| 2021 | 11 | 11 | 22 |
| 2022 | 3 | 7 | 10 |
| 2023 | 5 | 5 | 10 |
| 2024 | 11 | 7 | 18 |
| 2025 | 11 | 7 | 18 |
| 2026 | 10 | 5 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy-Resistant Breast Cancer. Mol Cancer Res. 2026 Sep 02; 24(9):784-800.
-
Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers. Gynecol Oncol. 2026 Sep; 212:134-144.
-
Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2026 Jul 17; 32(14):3018-3030.
-
American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults. Blood Adv. 2026 Jul 14; 10(13):4726-4756.
-
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial. Nat Commun. 2026 May 08; 17(1).
-
Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure. J Ovarian Res. 2026 Apr 25; 19(1).
-
Hypoxia Increases Connexin46 and Connexin43 Levels in KNS-42 Glioblastoma Cells. Int J Mol Sci. 2026 Mar 21; 27(6).
-
Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistance. Mol Cancer. 2026 Mar 03; 25(1).
-
Targeting Melanoma-Associated Fibroblasts to Overcome Cancer Stem Cell-Driven Drug Resistance. J Am Coll Surg. 2026 Apr 01; 242(4):761-771.
-
Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs. Cancer Prev Res (Phila). 2026 02 06; 19(2):79-92.